The American Association for Cancer Research (AACR) has released the AACR Cancer Progress Report 2024. The report highlights research-driven advances against the collection of devastating diseases we call cancer.
Read the ReportCancer is not a single disease, but rather a collection of diseases all characterized by the uncontrolled proliferation of cells.
Learn MoreA postdoctoral fellowship grant from the AACR helped propel Dr. Marco Ruella’s research to improve immunotherapy for patients whose disease evaded prior treatment or relapsed.
Learn MoreSeptember is Ovarian Cancer Awareness Month. Nearly 20,000 women in the U.S. are expected to be diagnosed with ovarian cancer this year. Read about prevention, screening, and treatment options.
Learn MoreThe current issue of Leading Discoveries features articles on AACR President Patricia M. LoRusso’s efforts to improve clinical trials, an AACR initiative on communicating science effectively, and much more.
Read Leading DiscoveriesMaking Treatment Decisions: Abigail Johnston shares how she has approached decisions about her cancer care since she was diagnosed with metastatic breast cancer in 2017.
Read Practical KnowledgeWhether honoring a special person or a special day, a donation to the American Association for Cancer Research has a lasting impact.
Donate NowView news and highlights from the AACR Annual Meeting 2024.
The AACR Cancer Disparities Progress Report 2024 outlines the complex interplay of factors that drive and perpetuate cancer health disparities and calls for a collaborative approach to achieve health equity.
Learn MoreThe AACR and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreDr. Winn, chair of the AACR Cancer Disparities Progress Report 2024 steering committee, discusses the many factors that drive and perpetuate cancer health disparities.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2021
Learn Moretherapeutics were approved for new or expanded uses by the FDA from July 1, 2023, to June 30, 2024
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn More